 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > ImmunoGen, Inc.
 |
ImmunoGen, Inc. |
 |
 |
 |
NEWS FROM THE WIRES |
 |
After The Bell - HP up, Dell down in rocky trading Aug 16 2001 03:28 PM PDT
After The Bell - HP up, Dell down in rocky trading Aug 16 2001 03:28 PM PDT
ImmunoGen moves to loss from profit in fiscal 4th-qtr Aug 16 2001 01:21 PM PDT
ImmunoGen moves to loss from profit in fiscal 4th-qtr Aug 16 2001 01:21 PM PDT
> More WIRE STORIES about this company
PROFILE |
 |
ImmunoGen is TAPping into cancer research. The development-stage firm's product candidates are TAPs (tumor-activated prodrugs) that deliver chemotherapy agents to a tumor without harming healthy cells. ImmunoGen and partner SmithKline Beecham (now GlaxoSmithKline) are developing a TAP drug candidate to treat colorectal, pancreatic, and non-small-cell lung cancers. Other development partners include Genentech (involving that firm's Herceptin breast cancer treatment), British Biotech, and Abgenix. Subsidiary Apoptosis Technology is researching programmed cell death (apoptosis) to discover treatments for cancers. ImmunoGen continues seeking partners to help fund its development activities.
COMPETITION |
 |
Cell Pathways, Inc. (CLPA)
ILEX Oncology, Inc. (ILXO)
NeoRx Corporation (NERX)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: June
2000 Sales (mil.): 11.20
1-Yr. Sales Growth: 202.7%
Employees: 60
Revenue per employee: $186,666.67
KEY PEOPLE |
 |
Mitchel Sayare
CEO
Gregg D. Beloff
CFO
CONTACT INFO |
 |
128 Sidney St.
Cambridge, MA 02139
US
Phone: 617-995-2500
Fax: 617-995-2510
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |